aTyr Pharma, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2005

Location

San Diego CA US

Primary Industry

Biotechnology

About

Founded in 2005 and based in California, US, aTyr Pharma, Inc. develops Physiocrine-based therapeutics for the treatment of rare diseases. The company's clinical product candidate, ATYR1923, a selective modulator of Neuropilin-2 (NRP2), is a potential disease-modifying therapy to deregulate the innate and adaptive immune responses in patients with severe inflammatory lung diseases. aTyr Pharma, Inc. also develops an Investigational New Drug (IND) candidate, ATYR2810, a monoclonal antibody and a potential treatment for certain aggressive solid tumors. ATYR2810 is in a pre-clinical development stage, that blocks the interaction between NRP2 and VEGF.

Current Investors

SLR Capital Partners, Silicon Valley Bank, Viking Global Investors

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopolymers, Biopharmaceuticals, Bioinformatics

Website

www.atyrpharma.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.